Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population-Reference-Cited by-同舟云学术

Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population

Published:2020-03-19 Issue:4 Volume:34 Page:425-432
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Boffa Giacomo,Bruschi Nicolò,Cellerino Maria,Lapucci Caterina,Novi Giovanni,Sbragia Elvira,Capello Elisabetta,Uccelli Antonio,Inglese Matilde

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology

Link

http://link.springer.com/content/pdf/10.1007/s40263-020-00714-8.pdf

Reference32 articles.

1. Fox EJ, Buckle GJ, Singer B, Singh V, Boster A. Lymphopenia and DMTs for relapsing forms of MS: considerations for the treating neurologist. Neurol Clin Pract. 2019;9(1):53–63.

2. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–15.

3. Calabresi PA, Radue E-W, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545–56.

4. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–97.

5. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–107.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lymphocytes and Infection in Autoimmune Diseases;Infection and Autoimmunity;2024

2. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study;Journal of Neurology, Neurosurgery & Psychiatry;2023-09-29

3. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate;Multiple Sclerosis and Related Disorders;2023-06

4. miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod;Journal of Neuroinflammation;2023-05-30

5. Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method;Therapeutic Advances in Neurological Disorders;2023-01